Summary
GlobalData, the industry analysis specialist's new report, "Acute Ischemic Stroke-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global Acute Ischemic Stroke (AIS) market. The report identifies the key trends shaping and driving the global AIS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global AIS sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global AIS market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The pipeline candidates fall under the major categories like thrombolytics, neuroprotectants, anticoagulants, antiplatelets.
-Analysis of the current and future market competition in the global AIS market. Key future market players covered are Lundbeck, ThromboGenics and Vernalis holding the molecules that can directly treat the acute phase of the disease in the pipeline. Apart from these companies, Bayer, Bristol-Myers Squibb and Boehringer Ingelheim are found to be the companies with noticeable Phase III molecules for conditions like stroke prevention in atrial fibrillation.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with AIS.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global AIS market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global AIS market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global AIS market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Acute Ischemic Stroke Market: Market Characterization
2.1 Overview
2.2 Acute Ischemic Stroke Market Size
2.3 Acute Ischemic Stroke Market Forecast and CAGR
2.4 Drivers and Barriers for the Acute Ischemic Stroke Market
2.4.1 Drivers for the Acute Ischemic Stroke Market
2.4.2 Barriers for the Acute Ischemic Stroke Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway
3 Acute Ischemic Stroke Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Product in the Acute Ischemic Stroke Market
3.3.1 Activase (alteplase)
3.3.2 Antiplatelets
3.3.3 Anticoagulants
3.4 Key Takeaway
4 Acute Ischemic Stroke Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 Acute Ischemic Stroke Therapeutics-Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Desmoteplase
4.4.2 Microplasmin
4.4.3 V10153
4.4.4 DP-b99
4.4.5 Citicoline
4.4.6 Rivaroxaban (BAY59-7939)
4.4.7 Apixaban
4.4.8 Dabigatran
4.5 Acute Ischemic Stroke Therapeutics Market-Clinical Pipeline by Mechanism of Action
4.6 Acute Ischemic Stroke Pipeline-Pipeline by Clinical Phases of Development
4.6.1 Acute Ischemic Stroke Therapeutics-Phase III Clinical Pipeline
4.6.2 Acute Ischemic Stroke Therapeutics-Phase II Clinical Pipeline
4.6.3 Acute Ischemic Stroke Therapeutics-Phase I Clinical Pipeline
4.6.4 Acute Ischemic Stroke Therapeutics-Preclinical Pipeline
4.6.5 Discontinued/Suspended Drugs for Acute Ischemic Stroke
4.7 Key Takeaway
5 Acute Ischemic Stroke Market: Implications for Future Market Competition
6 Acute Ischemic Stroke Market: Future Players in the Acute Ischemic Stroke Market
6.1 Introduction
6.2 Lundbeck
6.2.1 Overview
6.2.2 CNS Portfolio
6.2.3 Acute Ischemic Stroke Portfolio
6.3 ThromboGenics
6.3.1 Overview
6.3.2 CNS Portfolio
6.3.3 Acute Ischemic Stroke Product Portfolio
6.4 Vernalis
6.4.1 Overview
6.4.2 CNS Portfolio
6.5 Bayer
6.5.1 Overview
6.5.2 CNS Portfolio
6.5.3 Acute Ischemic Stroke Product Portfolio
6.6 Bristol-Myers Squibb
6.6.1 Overview
6.6.2 CNS Portfolio
6.6.3 Acute Ischemic Stroke Product Portfolio
6.7 Boehringer Ingelheim
6.7.1 Overview
6.7.2 CNS Portfolio
6.7.3 Acute Ischemic Stroke Portfolio
7 Acute Ischemic Stroke Market: Appendix
7.1 Definition
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panel Validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

List of Tables
1.1 List of Tables
Table 1: Global Acute Ischemic Stroke Therapeutics Market, Revenue Forecasts, 2000-2008
Table 2: Global Acute Ischemic Stroke Therapeutics Market, Revenue Forecasts, 2009-2015
Table 3: Marketed Product Analysis in the Acute Ischemic Stroke Market, 2009
Table 4: Acute Ischemic Stroke Therapeutics-Most Promising Drugs under Clinical Development, 2009
Table 5: Acute Ischemic Stroke Therapeutics-Phase III Clinical Pipeline, 2009
Table 6: Acute Ischemic Stroke Therapeutics-Phase II Clinical Pipeline, 2009
Table 7: Acute Ischemic Stroke Therapeutics-Phase I Clinical Pipeline, 2009
Table 8: Acute Ischemic Stroke Therapeutics-Preclinical Pipeline, 2009
Table 9: List of Discontinued Drugs for Acute Ischemic Stroke, 2009
Table 10: Lundbeck-CNS Marketed Products, 2009
Table 11: Lundbeck-CNS Pipeline Products, 2009
Table 12: ThromboGenics-CNS Pipeline Products, 2009
Table 13: Vernalis-CNS Marketed Products, 2009
Table 14: Vernalis-CNS Pipeline Products, 2009
Table 15: Bayer-CNS Marketed Products, 2009
Table 16: Bayer-CNS Pipeline Products, 2009
Table 17: Bristol-Myers Squibb-CNS Marketed Products, 2009
Table 18: Bristol-Myers Squibb-CNS Pipeline Products, 2009
Table 19: Boehringer Ingelheim-CNS Marketed Products, 2009
Table 20: Boehringer Ingelheim-CNS Pipeline Products, 2009

List of Figures
1.2 List of Figures
Figure 1: Global Acute Ischemic Stroke Market Forecast, 2000-2015
Figure 2: Opportunity and Unmet Need in the Acute Ischemic Stroke Market, 2009
Figure 3: Strategic Competitor Assessment of the Marketed Products for Acute Ischemic Stroke, 2009
Figure 4: Technology Trends Analytic Framework of the Acute Ischemic Stroke Pipeline, 2009
Figure 5: Technology Trends Analytic Framework of the Acute Ischemic Stroke Pipeline-Description, 2009
Figure 6: Acute Ischemic Stroke Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2009
Figure 7: Acute Ischemic Stroke Pipeline by Phase of Clinical Development, 2009
Figure 8: Implications for Future Market Competition in the Acute Ischemic Stroke Market, 2009
Figure 9: Acute Ischemic Stroke Therapeutics Market-Clinical Pipeline by Company, 2009
Figure 10: GlobalData Methodology
Figure 11: GlobalData  Market Forecasting Model